Andrea Jones, MD
Allergy & Immunology · Davenport, IANPI 1750673984
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,225 of the $2,538 with a category attached, or 87.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations.
Across 121 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$564
- Sanofi$373
- GSK$280
- Sanofi-aventis U.S. LLC$239
- Regeneron Healthcare Solutions, Inc.$153
- Takeda Pharmaceuticals U.S.A., Inc.$136
- plus $792 from 16 others
What the payments were for
- Food & beverage$2,22588%
- Education$31312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $564 |
| Sanofi | 30 | $373 |
| GSK | 20 | $280 |
| Sanofi-aventis U.S. LLC | 3 | $239 |
| Regeneron Healthcare Solutions, Inc. | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $136 |
| Octapharma USA, Inc. | 3 | $125 |
| Biogen | 1 | $120 |
| Grifols USA, LLC | 5 | $86 |
| Teva Pharmaceuticals USA, Inc. | 5 | $85 |
| Pfizer | 4 | $57 |
| Novartis | 3 | $56 |
| Kaleo, Inc. | 2 | $43 |
| Genentech USA, Inc. | 3 | $42 |
| CSL Behring | 2 | $34 |
| Greer Laboratories, Inc. | 1 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Alk-abello, Inc | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Pharming Healthcare, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,538 in reported general payments places this provider in the 70th percentile of 32 allergy & immunology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IcatibantIcatibant Acetate | 14 | $1,037,595 |
| TakhzyroLanadelumab-Flyo | 12 | $902,645 |
| Dupixent PenDupilumab | 17 | $72,930 |
| NucalaMepolizumab | 13 | $55,672 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,874 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,759 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,943 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,920 |
| Qvar RedihalerBeclomethasone Dipropionate | 16 | $5,754 |
| DuleraMometasone/Formoterol | 15 | $5,728 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $4,907 |
| Arnuity ElliptaFluticasone Furoate | 17 | $4,429 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,021 |
| Epinephrine | 18 | $2,872 |
| Montelukast Sodium | 151 | $1,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $136 | $902,64512 claims |
| GSKNucala, Trelegy Ellipta, Arnuity Ellipta, Incruse Ellipta | $280 | $95,99680 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $564 | $16,67939 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $85 | $5,75416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 32 allergy & immunology providers in Iowa.
Other allergy & immunology in Davenport
- Karen MavesDavenport$192
- Vuong NayimaWest Des Moines$34K
- Fadi AlkhatibWest Des Moines$16K
- Daniel HamilosMason City$11K
- Lyla SchweigerCedar Rapids$6K
- Edward NassifAmes$5K
- Holly BrownCedar Rapids$4K
- Whitney MolisDes Moines$4K
- Safia NawazDes Moines$4K
- Robert SmithSioux Center$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.